Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm
Alongside decisions involving capacity expansion, officials at Samsung Biologics announced that the company is pursuing opportunities to broaden its portfolio and address an increasingly diverse range of therapeutic modalities. The post Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm appeared first on GEN - Genetic Engineering and Biotechnology News .
Samsung Biologics has secured a $262 million manufacturing agreement with an undisclosed European pharmaceutical firm. Under the contract, production activities will be carried out at the company's state-of-the-art Songdo facility in South Korea until 2033. The agreement brings Samsung Biologics' total contract value to over $21.9 billion.
The company currently operates 845 kiloliters of manufacturing capacity, with 785 kiloliters located in Songdo and 60 kiloliters in its Rockville, Maryland facility. The Rockville site marks Samsung Biologics' first U.S. manufacturing presence, which was acquired in March 2026. To further strengthen its global footprint, Samsung Biologics has established offices in New Jersey, Boston, Tokyo, and Amsterdam.
The company is also in the process of acquiring land for Bio Campus III, a planned site set to support advanced R&D and manufacturing programs for next-generation therapeutics. Samsung Biologics remains committed to expanding its capacity and capability, evaluating additional investments as market demand and client needs evolve.
The company is also exploring opportunities to broaden its product portfolio, including the acquisition of PolyPeptide Group, which would add peptide-based therapeutics to Samsung Biologics' offerings and diversify its global manufacturing network.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
